AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average – What’s Next?

AstraZeneca PLC (LON:AZN) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of £134.71 and traded as high as £140.80. AstraZeneca shares last traded at £140.76, with a volume of 214,151,109 shares traded.

Analyst Ratings Changes

A number of analysts have recently commented on AZN shares. Citigroup began coverage on AstraZeneca in a research note on Tuesday, January 27th. They set a “buy” rating and a £170 price target on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Finally, Berenberg Bank boosted their target price on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of £145.83.

AstraZeneca Price Performance

The company has a fifty day simple moving average of £143.94 and a 200 day simple moving average of £134.71. The stock has a market capitalization of £218.28 billion, a price-to-earnings ratio of 21.52, a P/E/G ratio of 0.86 and a beta of 0.23. The company has a debt-to-equity ratio of 60.87, a quick ratio of 0.59 and a current ratio of 0.94.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.